Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Differentiation of tumours of ductal and lobular origin: II. Genomics of invasive ductal and lobular breast carcinomas

G. Turashvili, J. Bouchal, G. Burkadze, Z. Kolár

. 2005 ; 149 (1) : 63-68.

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc13003792

Grantová podpora
NR7844 MZ0 CEP - Centrální evidence projektů

Breast cancer is considered to be a multifactorial disorder caused by both genetic and non-genetic factors. Different histological types of breast cancer differ in response to treatment and may have a divergent clinical course. Breast tissue is heterogeneous, with components of epithelial, mesenchymal, endothelial and lymphopoietic derivation. The genetic heterogeneity of invasive breast cancer is reflected by the wide spectrum of histological types and differentiation grades. Nevertheless, the influences of these cell types on the tumour's total pattern of gene expression can be estimated analytically. Microarrays permit total tissue analysis and provide a stable molecular portrait of tumours. Some investigations suggest differences in the gene expression profiling for ductal and lobular carcinomas. It has been reported that inactivating mutations of the E-cadherin gene are very frequent in infiltrating lobular breast carcinomas. Other than altered expression of E-cadherin, little is known about the underlying biology that distinguishes ductal and lobular tumour subtypes. However, about 8 genes have been identified differentially which are expressed in lobular and ductal cancers: E-CD, survivin, cathepsin B, TPI1, SPRY1, SCYA14, TFAP2B, and thrombospondin 4, osteopontin, HLA-G, and CHC1. Expression profiling of breast cancers can be used diagnostically to distinguish individual histologic subclassifications and may guide the selection of target therapeutics. However, future approaches will need to include methods for high throughput clinical validation and the ability to analyze microscopic samples.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13003792
003      
CZ-PrNML
005      
20130909144253.0
007      
ta
008      
130128s2005 xr f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2005.006 $2 doi
035    __
$a (PubMed)16170390
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Turashvili, Gullisa. $7 _AN040279 $u Laboratory of Molecular Pathology and Institute of Pathology, Palacky University, Olomouc
245    10
$a Differentiation of tumours of ductal and lobular origin: II. Genomics of invasive ductal and lobular breast carcinomas / $c G. Turashvili, J. Bouchal, G. Burkadze, Z. Kolár
520    9_
$a Breast cancer is considered to be a multifactorial disorder caused by both genetic and non-genetic factors. Different histological types of breast cancer differ in response to treatment and may have a divergent clinical course. Breast tissue is heterogeneous, with components of epithelial, mesenchymal, endothelial and lymphopoietic derivation. The genetic heterogeneity of invasive breast cancer is reflected by the wide spectrum of histological types and differentiation grades. Nevertheless, the influences of these cell types on the tumour's total pattern of gene expression can be estimated analytically. Microarrays permit total tissue analysis and provide a stable molecular portrait of tumours. Some investigations suggest differences in the gene expression profiling for ductal and lobular carcinomas. It has been reported that inactivating mutations of the E-cadherin gene are very frequent in infiltrating lobular breast carcinomas. Other than altered expression of E-cadherin, little is known about the underlying biology that distinguishes ductal and lobular tumour subtypes. However, about 8 genes have been identified differentially which are expressed in lobular and ductal cancers: E-CD, survivin, cathepsin B, TPI1, SPRY1, SCYA14, TFAP2B, and thrombospondin 4, osteopontin, HLA-G, and CHC1. Expression profiling of breast cancers can be used diagnostically to distinguish individual histologic subclassifications and may guide the selection of target therapeutics. However, future approaches will need to include methods for high throughput clinical validation and the ability to analyze microscopic samples.
650    _2
$a nádory prsu $x diagnóza $x genetika $7 D001943
650    _2
$a duktální karcinom prsu $x diagnóza $x genetika $7 D018270
650    _2
$a lobulární karcinom $x diagnóza $x genetika $7 D018275
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů $7 D020411
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Bouchal, Jan, $d 1973- $7 xx0034399 $u Laboratory of Molecular Pathology and Institute of Pathology, Palacky University, Olomouc
700    1_
$a Burkadze, George $u Department of Pathology, Tbilisi State Medical University, Tbilisi, Georgia
700    1_
$a Kolář, Zdeněk, $d 1953- $7 jn20000710256 $u Laboratory of Molecular Pathology and Institute of Pathology, Palacky University, Olomouc
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic $x 1213-8118 $g Roč. 149, č. 1 (2005), s. 63-68
910    __
$a ABA008 $b A 1502 $c sign $y 3 $z 0
990    __
$a 20130128 $b ABA008
991    __
$a 20130909144748 $b ABA008
999    __
$a ok $b bmc $g 966446 $s 801987
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2005 $b 149 $c 1 $d 63-68 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
GRA    __
$a NR7844 $p MZ0
LZP    __
$b NLK111 $a Pubmed-20130128

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...